Michelle Dalton

Experts weigh in on Retina Subspecialty Day
Drs. Wykoff, Kim and Spaide summarize day-two of Retina Subspecialty Day at AAO 2017
Drs. Wykoff, Kim and Spaide summarize day-two of Retina Subspecialty Day at AAO 2017
Uveitis updates from Retina Subspecialty Day 2017
Highlights from Day 2 of Retina Subspecialty Day 2017
Real-world outcomes with aflibercept better in treatment-naïve patientsAfter 12 months of treatment with intravitreal aflibercept injections, both treatment-naïve and pre-treated patients demonstrated visual acuity gains. Visual acuity improvement was higher in treatment-naïve patients.
Failed cell therapy study offers positives, raises new questionsPatients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
Treat-and-extend may lead to better AMD resultsTreating neovascular age-related macular degeneration (nAMD) patients with anti-vascular endothelial growth factor (anti-VEGF) ranibizumab (Lucentis, Genentech) on a monthly regimen has produced “great results” in clinical trials, said Prof. Mark C. Gillies, MBBS, PhD. “But what happens after that and what happens in real world practice?”
‘Ideal’ disease control leads to better nAMD outcomesNeovascular age-related macular degeneration (nAMD) is well-known as a heterogeneous disease with variable natural history and variable treatment response, said Carl D. Regillo, MD, FACS. Many patients do well without monthly treatment as noted in HARBOR PRN arms.
Future of DME resting on new mechanisms of actionWhen it comes to finding new treatments for diabetic macular edema (DME), there is no shortage of promising targets, said Peter A. Campochiaro, MD. He presented an overview of future compounds with various mechanisms of action that may change how clinicians treat DME.
Reducing pain during postop pediatric strabismus surgeryIn a randomized study, patients receiving bupivocaine had lower pain scores than the control group in the first 30 minutes after surgery. However, other factors may also play a role.